Merck 4-week hep C regimen with Gilead's Sovaldi comes up short<p><a href="http://news.yahoo.com/merck-four-week-hep-c-regimen-gileads-sovaldi-001648224--finance.html"><img src="http://l3.yimg.com/bt/api/res/1.2/GaXQ6hUf79ugro_zfclzlg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-11-10T001627Z_1_LYNXNPEAA9005_RTROPTP_2_VERTEX.JPG" width="130" height="86" alt="Branch of drugs and chemicals group Merck is pictured in central German city of Darmstadt" align="left" title="Branch of drugs and chemicals group Merck is pictured in central German city of Darmstadt" border="0" /></a>By Bill Berkrot (Reuters) - An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study. Several companies have been working to find ways to further reduce the number of weeks of treatment needed, while keeping cure rates above 90 percent. ...</p><br clear="all"/>
Source: Merck 4-week hep C regimen with Gilead's Sovaldi comes up short (http://news.yahoo.com/merck-four-week-hep-c-regimen-gileads-sovaldi-001648224--finance.html)